patients undergo surgery worldwide each year, around 25% of whom will develop complications. 4 -6 Estimates of hospital mortality rates for in-patient non-cardiac surgery may be as high as 2-4%. 1 -6 Long-term survival is significantly reduced after surgery for those patients who develop complications but survive to leave hospital. 5 7 Importantly, around 80% of deaths occur among a subgroup of patients who can be identified as being at high risk before surgery is performed. 2 3 Typical risk factors for postoperative complications include advanced age, co-morbid disease, and major surgery. However, evidence suggests that most patients who meet these high-risk criteria do not receive additional care to improve the prospect of good postoperative outcomes. 1 -3 One reason for this may be the subjective nature of the current approach to clinical assessment of risk which often requires a doctor to make the case for additional care for individual high-risk patients. An alternative approach may be the use of objective measures of risk including scoring systems, 8 9 plasma biomarkers, 10 -21 and cardiopulmon-However, few data are available to provide direct comparisons between the most promising candidate methods. Our aim was to undertake a pilot study to compare the prognostic accuracy of CPET and the plasma biomarkers B-type natriuretic peptide (BNP), estimated glomerular filtration rate (eGFR; calculated from serum creatinine), and C-reactive protein (CRP) to the most commonly used clinical scoring systems to predict complications among patients undergoing elective major non-cardiac surgery.
Methods

Patients
This was a single-centre observational study of adult patients aged 40 yr and over, undergoing major elective non-cardiac surgery at the Royal London Hospital, London, UK. The study was approved prospectively by the East London and City Research ethics committee (reference 09/H0704/23) and written informed consent was given by all patients before enrolment. Exclusion criteria were unsuitability for CPET based on the American Thoracic Society guidelines, 27 pregnancy, and refusal of consent. Potential participants were screened by local investigators having been identified in a consultant-led preoperative assessment clinic. The decision to offer surgery and allocation of postoperative critical care were made on the basis of established clinical protocols which did not include consideration of CPET data. However, CPET data were made available to anaesthetic staff on specific request. Plasma biomarker data were not made available to clinical staff. ASA physical status score was documented on the anaesthetic chart for all patients. Revised cardiac risk index (RCRI) is not routinely calculated by clinical staff.
Preoperative data
Baseline clinical data were collected allowing calculation of RCRI and the Portsmouth Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (P-POSSUM). 8 28 The ASA score (assessed by the attending anaesthetist) was also noted. Patients were then asked to lie quietly in the supine position before venepuncture. Within 30 min of collection, blood samples were centrifuged at 4300 rpm for 10 min and stored at 2808C for subsequent analysis. BNP was analysed by immunoassay (Architect i2000SR, Abbott Diagnostics, USA). The measuring interval was 10 -5000 pg ml 21 , the average analytical coefficient of variation was ,5%, and the reference interval was ,135 pg ml 21 . CRP was analysed using an immunoturbidimetric method (Architect c16000, Abbott Diagnostics) with a measuring interval of 0.1-160 mg litre 21 . The average analytical coefficient of variation was ,2%, and the reference interval was ,7 mg litre 21 . eGFR was calculated from age and serum creatinine with adjustment for ethnicity using the modification of diet in renal disease equation. 29 Creatinine was analysed using a kinetic Jaffe reaction assay (Roche Diagnostics, Switzerland). On the day of exercise testing, patients were fasted for 2 h and refrained from caffeine in accordance with American Thoracic Society guidelines. 27 They were seated on a computer-controlled, electromagnetically braked cycle ergometer and cycled at a cadence of 55-65 rpm. Subjects wore a tight facemask to permit continuous measurements of ventilation, oxygen consumption (VO 2 ), and carbon dioxide production (VCO 2 ) in expired gas. These measurements allowed estimation of peak oxygen consumption (VO 2 peak) and anaerobic threshold (AT) using a modified V-slope method. Arterial pressure, 12-lead ECG, and arterial pulse oximetry readings were taken at rest. During exercise, arterial pressure was measured every 3 min while pulse oximetry and ECG rhythm were monitored continuously. Subjects performed an incremental ramp test to the limit of tolerance. A ramp slope, based on gender, age, and estimated physical fitness of the subject, was set in order to obtain a test of 10 min duration. The limit of tolerance (maximum) was defined as the point at which the subject could not maintain a pedalling cadence of 55-65 rpm despite encouragement. All tests were supervised by a physician trained in the analysis of these tests. Criteria for stopping or preventing a subject from being tested were also based on American Thoracic Society guidelines. 27 
Postoperative data
After surgery, patients were followed up for 28 days by a research assistant who was not present at the exercise test. Data were collected describing pre-defined postoperative complications (Supplementary material) including major adverse cardiac events (MACE) (defined as myocardial infarction, cardiogenic pulmonary oedema, cardiac arrest, or complete heart block), 8 duration of hospital stay, and mortality.
The P-POSSUM score was completed for each patient immediately after surgery.
Statistical analysis
This was a pilot study to evaluate the feasibility and inform the design of a larger observational study. No formal sample size calculation was made. Instead, we planned to recruit 100 patients undergoing major surgery. Patients who were enrolled but did not subsequently undergo surgery were prospectively excluded from the analysis. Receiver operating characteristic (ROC) curves were constructed by first tabulating and then plotting the sensitivity and specificity of the test result at various cut-offs, then calculating the area under these curves (AUROC) to quantify overall prognostic discrimination for MACE and all complications. Categorical variables were tested with the Fisher's exact test. AUROC is presented with 95% confidence intervals. Optimal threshold values and associated sensitivities and specificities are presented for variables with AUROC .0.8 for the corresponding outcome (good predictive accuracy). Other data are presented as mean (SD) where normally distributed or median (IQR) where not normally distributed. Statistical analysis was performed using GraphPad Prism version 4.0 (GraphPad Software, USA).
Results
One hundred patients were recruited between April 2009 and October 2010. After preoperative assessment, 17 patients did not proceed to surgery ( Fig. 1 and Supplementary Table S1 ). A total of 83 patients who underwent CPET proceeded to surgery all of whom were followed up for 28 days. The median operating time was 270 min (198-378). All patients underwent general anaesthesia, 64 (77%) in combination with epidural analgesia. Patient characteristics are presented in Table 1 . Forty patients developed complications (48%); nine of whom developed MACE (11%) ( Table 2 ). There were three deaths, all of which followed MACE. The median duration of hospital stay was 12 days (7-22) and three patients died. For those patients alive at day 28, the median number of critical care free days was 25 (21) (22) (23) (24) (25) (26) . Clinicians made few requests for CPET data, but unfortunately, we did not document the frequency of these requests and did not record any qualitative data on how they influenced patient care. Univariate analysis of the association with outcomes for the candidate prognostic markers is presented in Table 3 (Fig. 2) . The predictive value of CPETderived variables was greater than that of scoring systems and plasma biomarkers. Both AT (sensitivity 75%, specificity 85% for an optimal threshold value of 10.6 ml min 21 kg 21 )
and VO 2 peak (sensitivity 88%, specificity 69% for an optimal threshold value of 14.0 ml min 21 kg 21 ) were good predictors of MACE and poor predictors of all complications (Fig. 3) .
Discussion
The principal findings of this small pilot study are that CPETand plasma biomarkers may have adequate prognostic accuracy in predicting which patients will develop complications after major non-cardiac surgery. CPET and biomarkers appeared to be more effective in the prediction of MACE than for unselected complications. Of the plasma biomarkers, BNP appeared to be the strongest prognostic marker followed by eGFR, while CRP was not predictive of any clinical outcomes. ASA score and RCRI were not predictive of overall complications in this small cohort and only poorly predictive of MACE. Our findings do not confirm the clinical utility of these tests but do suggest that a multi-centre study to confirm and extend these findings would be both feasible and worthwhile. These data may help in the estimation of event rates, and the rates of drop-out before and after surgery.
There is a growing evidence base describing the use of various tests for the prediction of postoperative outcomes. However, in many cases, this consists of small, single-centre case series with methodological limitations. In the case of CPET, there are few reports of the predictive accuracy of this test for complications after surgery. 22 -26 Two systematic reviews have suggested that CPET-derived variables are valid predictors of complications after non-cardiac surgery which may outperform alternative methods. 30 31 Recent evidence suggests that CPET-derived variables may also be predictive of long-term postoperative mortality. 32 However, there is substantial heterogeneity in the literature. Two studies, both notable for being clinician blinded, provide data describing the accuracy of CPET in predicting postoperative complications. 33 34 In the first study, AUROC of only 0.59 for AT and 0.66 for VO 2 peak are described, 33 while investigators in the more recent study report AUROC of 0.85 for AT (AUROC for VO 2 peak not reported). 34 Our findings are consistent with those of published studies suggesting a role for BNP in the preoperative assessment of risk. 11 -19 The findings of a systematic review also suggest a role for this biomarker, in particular in the prediction of MACE. 35 There are less published data describing the potential for eGFR in risk assessment before non-cardiac surgery patients but the available data are encouraging, 20 21 and it is interesting to note that preoperative serum creatinine was an independent risk factor for MACE in the work which defined RCRI. 8 We identified two publications exploring risk assessment with CRP and it is not possible to confirm the utility of this biomarker at the current time. 10 19 The findings of one study suggest some predictive value of preoperative CRP measurement, 10 while those of a more recent study suggested a weak relationship in keeping with our findings in the current study. 19 Recent data have demonstrated the value of the ASA score in describing the severity of co-morbid disease in a large patient cohort. 1 However, the limited number of categories limits the predictive value of the ASA score. This is especially the case because the five ASA categories were collapsed together into two categories to improve prognostic accuracy. We are not aware of any previous evaluation of the predictive value of the ASA score for postoperative complications. The current literature for preoperative prediction of postoperative complications is characterized by a number of common limitations for all the methods described here; most importantly, small sample size, a lack of clinician blinding, and retrospective methodology. 36 None of the published studies has compared all the candidate risk assessment tools in a single large patient cohort.
The strength of the current study is that it is, to our knowledge, the first comparison of CPET, plasma biomarkers, and scoring systems in the evaluation of the risk of postoperative complications before non-cardiac surgery. However, this work also has a number of important limitations. The sample size was small and susceptible to selection bias. Patients were already considered at sufficient risk to require referral to a consultant-led preoperative assessment clinic. Unfortunately, we did not document the frequency of clinician requests to view CPET data or how this may have influenced patient care. The profile of patients who developed MACE appeared to favour prediction of this outcome whereas the poor predictive accuracy for all complications may reflect the wider presence of risk factors for this outcome. Even among those patients at high risk, not every patient will develop complications because this outcome is also influenced by factors which occur during and after surgery. The high event rate for all complications suggests a uniformly high level of risk across all patients which might reduce the opportunity to discriminate between patients in terms of the preoperative characteristics associated with poor postoperative outcome. We did not perform a multivariate analysis because of the small sample size and anticipated low event rates which limit the number of variables which can be included in such models. These problems can only be resolved in a much larger clinical study with a wider distribution of perioperative risk to provide more robust estimates of predictive value and the associated discriminatory thresholds.
Conclusions
These pilot data suggest that CPET-derived variables and plasma biomarkers have the potential to predict complications, in particular cardiac complications, within 28 days of P-POSSUM morbidity probability (%) 50% (23) 55% (27) 50% (24) 71% (24) Ischaemic heart disease (%) 10 (23%) 13 ( surgery. Large multi-centre studies are now required to confirm the clinical utility of these prognostic tests. This would allow evaluation of each category of prognostic test (scoring systems, plasma biomarkers, and CPET biomarkers) and define how and if multiple tests may be used effectively in an integrated assessment of risk of MACE, overall complications, and postoperative death. Importantly, an integrated approach has the potential for low cost risk screening for all patients allowing both an individual risk assessment for each patient and risk-adjusted evaluation of outcomes using multivariate models, facilitating effective large-scale clinical audit and benchmarking between centres. These pilot data confirm the feasibility of large clinical studies of this type.
